These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature. Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802 [TBL] [Abstract][Full Text] [Related]
5. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review. Yang X; Xi R; Bai J; Pan Y Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229 [TBL] [Abstract][Full Text] [Related]
6. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755 [TBL] [Abstract][Full Text] [Related]
7. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome. Condliffe AM; Chandra A Front Immunol; 2018; 9():338. PubMed ID: 29556229 [TBL] [Abstract][Full Text] [Related]
8. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome. Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M Front Immunol; 2018; 9():568. PubMed ID: 29675019 [TBL] [Abstract][Full Text] [Related]
10. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy. Michalovich D; Nejentsev S Front Immunol; 2018; 9():369. PubMed ID: 29535736 [TBL] [Abstract][Full Text] [Related]
11. Systematic review of mortality and survival rates for APDS. Hanson J; Bonnen PE Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023 [TBL] [Abstract][Full Text] [Related]
12. A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects. Bildik HN; Esenboga S; Halaclı SO; Karaatmaca B; Aytekin ES; Nabiyeva N; Akarsu A; Ocak M; Erman B; Tan C; Arikoglu T; Yaz I; Cicek B; Tezcan I; Cagdas D Pediatr Allergy Immunol; 2024 Sep; 35(9):e14245. PubMed ID: 39312287 [TBL] [Abstract][Full Text] [Related]
13. Interim analysis: Open-label extension study of leniolisib for patients with APDS. Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893 [TBL] [Abstract][Full Text] [Related]
14. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes. Redenbaugh V; Coulter T Front Pediatr; 2021; 9():702872. PubMed ID: 34422726 [TBL] [Abstract][Full Text] [Related]
15. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S Front Immunol; 2018; 9():543. PubMed ID: 29599784 [TBL] [Abstract][Full Text] [Related]
16. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature. Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393 [TBL] [Abstract][Full Text] [Related]
17. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib. Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011 [TBL] [Abstract][Full Text] [Related]
18. Activated Phosphoinositide 3-Kinase δ Syndrome: a Large Pediatric Cohort from a Single Center in China. Qiu L; Wang Y; Tang W; Yang Q; Zeng T; Chen J; Chen X; Zhang L; Zhou L; Zhang Z; An Y; Tang X; Zhao X J Clin Immunol; 2022 May; 42(4):837-850. PubMed ID: 35296988 [TBL] [Abstract][Full Text] [Related]
19. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. Maccari ME; Wolkewitz M; Schwab C; Lorenzini T; Leiding JW; Aladjdi N; Abolhassani H; Abou-Chahla W; Aiuti A; Azarnoush S; Baris S; Barlogis V; Barzaghi F; Baumann U; Bloomfield M; Bohynikova N; Bodet D; Boutboul D; Bucciol G; Buckland MS; Burns SO; Cancrini C; Cathébras P; Cavazzana M; Cheminant M; Chinello M; Ciznar P; Coulter TI; D'Aveni M; Ekwall O; Eric Z; Eren E; Fasth A; Frange P; Fournier B; Garcia-Prat M; Gardembas M; Geier C; Ghosh S; Goda V; Hammarström L; Hauck F; Heeg M; Heropolitanska-Pliszka E; Hilfanova A; Jolles S; Karakoc-Aydiner E; Kindle GR; Kiykim A; Klemann C; Koletsi P; Koltan S; Kondratenko I; Körholz J; Krüger R; Jeziorski E; Levy R; Le Guenno G; Lefevre G; Lougaris V; Marzollo A; Mahlaoui N; Malphettes M; Meinhardt A; Merlin E; Meyts I; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neubert J; Neven B; Nieters A; Nove-Josserand R; Oksenhendler E; Ozen A; Olbrich P; Perlat A; Pac M; Schmid JP; Pacillo L; Parra-Martinez A; Paschenko O; Pellier I; Sefer AP; Plebani A; Plantaz D; Prader S; Raffray L; Ritterbusch H; Riviere JG; Rivalta B; Rusch S; Sakovich I; Savic S; Scheible R; Schleinitz N; Schuetz C; Schulz A; Sediva A; Semeraro M; Sharapova SO; Shcherbina A; Slatter MA; Sogkas G; Soler-Palacin P; Speckmann C; Stephan JL; Suarez F; Tommasini A; Trück J; Uhlmann A; van Aerde KJ; van Montfrans J; von Bernuth H; Warnatz K; Williams T; Worth AJJ; Ip W; Picard C; Catherinot E; Nademi Z; Grimbacher B; Forbes Satter LR; Kracker S; Chandra A; Condliffe AM; Ehl S; J Allergy Clin Immunol; 2023 Oct; 152(4):984-996.e10. PubMed ID: 37390899 [TBL] [Abstract][Full Text] [Related]